Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMolecular Partners AG

Molecular Partners AG

PortfolioPortfolio WatchlistWatchlist
Company price
3.04 GBX 0.04 ( 1.33%)
Last update at 2026-10-26T10:30:00Z
VOLUME
475
Market Cap
57.51M
P/E
0.01

Momentum Score

…

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.04
Low
3.04
High
52 Week Price Range
2.72
Low
3.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-39.14M
Debt / Equity
0.05
ROE
-55.55%
Net Debt
-79.01M
ROCE
-60.83%
Diluted EPS TTM
3.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -61.65M -54.04M -61.98M 117.85M -63.78M
Net income -61.65M -54.04M -61.98M 117.85M -63.78M
Selling general administrative - 17.16M 19.00M - -
Gross profit -2.15M -42.53M -40.81M 138.85M -45.96M
Ebit -55.40M -54.00M -61.94M 116.61M -63.42M
Ebitda -53.26M -51.63M -59.52M 117.50M -62.44M
Depreciation and amortization 2.15M 2.37M 2.42M 0.89M 0.97M
Operating income -55.44M -61.22M -61.11M 116.61M -63.42M
Other operating expenses 55.44M 66.19M 68.15M 72.28M 73.09M
Interest expense 3.50M 0.04M 0.05M - 0.00M
Income tax expense 0.00M 0.00M 2.25M - 0.00M
Total revenue - 4.97M 7.04M 189.60M 9.75M
Total operating expenses 53.29M 18.68M 20.30M 21.54M 17.37M
Cost of revenue 2.15M 47.50M 47.84M 50.75M 55.72M
Total other income expense net -6.21M 7.18M -0.88M 1.24M -0.36M
Net income applicable to common shares - - - 117.85M -63.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 102.11M 158.53M 198.35M 262.26M 172.67M
Intangible assets 0.00M 0.05M 0.21M 0.27M 0.33M
Other current assets 2.52M 3.73M 2.49M 5.09M 7.67M
Total liab 21.77M 16.89M 21.92M 27.09M 65.38M
Total stockholder equity 80.33M 141.64M 176.43M 235.17M 107.29M
Other current liab 8.88M 7.67M 8.46M 16.25M 42.00M
Common stock 4.04M 4.04M 3.63M 3.60M 3.23M
Retained earnings -311.75M -246.29M -191.75M -127.78M -250.95M
Other liab - - - 6.19M 13.66M
Other assets - - - -0.00M -
Cash 82.65M 63.87M 67.31M 87.95M 71.81M
Total current liabilities 11.03M 10.79M 14.42M 17.25M 46.87M
Current deferred revenue - - 4.33M - -
Net debt -79.01M -61.43M -63.66M -87.95M -71.81M
Short term debt 1.21M 2.43M 1.21M - -
Short long term debt total 3.64M 2.44M 3.65M - -
Other stockholder equity 388.05M 383.89M 364.55M 359.34M 355.01M
Property plant equipment - - - 7.24M 8.15M
Total current assets 96.88M 154.28M 192.46M 254.75M 164.19M
Net tangible assets - - - 234.90M 106.96M
Short term investments 10.40M 85.56M 119.58M 161.20M 61.00M
Net receivables 1.30M 1.11M 1.75M 0.52M 23.71M
Inventory - - - - 0.00M
Accounts payable 0.94M 0.68M 0.41M 1.00M 4.86M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other - - 0.21M -7.51M -8.48M
Non current assets total 5.23M 4.25M 5.89M 7.51M 8.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - -100.20M -21.00M
Change to liabilities - - - -30.53M -8.99M
Total cashflows from investing activities 70.82M 40.49M 44.64M -101.12M -22.24M
Net borrowings - - - -1.19M -1.18M
Total cash from financing activities -1.15M 14.43M -1.17M -1.57M 50.58M
Change to operating activities - - - -0.74M -2.30M
Net income -61.65M -54.04M -61.98M 117.85M -63.78M
Change in cash -56.38M -3.44M -20.64M 16.13M -61.91M
Begin period cash flow 149.44M 67.31M 87.95M 71.81M 133.72M
End period cash flow 93.06M 63.87M 67.31M 87.95M 71.81M
Total cash from operating activities -49.53M -59.25M -59.01M 118.57M -90.95M
Depreciation - 2.37M 2.42M 2.09M 2.17M
Other cashflows from investing activities 71.54M 4.22M 3.83M 0.49M 0.07M
Change to account receivables 0.48M -0.35M -0.93M 25.26M -23.37M
Sale purchase of stock - - - -0.63M -
Other cashflows from financing activities -1.21M -1.70M 0.03M 0.25M 51.76M
Change to netincome - - - 4.33M 4.93M
Capital expenditures 0.71M 0.72M 0.57M 1.18M 0.93M
Change in working capital 1.21M -3.80M -6.01M 25.26M -23.37M
Stock based compensation - 4.11M 5.21M 5.09M 4.08M
Other non cash items 10.91M -7.88M 1.36M -31.73M -10.05M
Free cash flow -50.24M -59.97M -59.81M 117.39M -91.89M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0QXX
Molecular Partners AG		 0.04
1.33%		 3.04 0.01 - 78.60 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Wagistrasse 14, Schlieren, Switzerland, 8952

41 44 755 77 00

https://www.molecularpartners.com

134

Name Title Year Born
Dr. Patrick Amstutz Ph.D. Co-Founder, CEO, Member of Management Board & Director 1975
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Exec. VP of Projects & Member of Management Board 1972
Mr. Andreas Emmenegger E.M.B.A. Advisor 1966
Mr. Alexander Zurcher COO & Member of Management Board NA
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA Chief Medical Officer & Member of Management Board 1973
Ms. Renate Gloggner Exec. VP of People & Community and Member of Management Board NA
Mr. Daniel Steiner Ph.D. Sr. VP of Research NA
Mr. Seth D. Lewis Sr. VP of Investor Relations, Communications & Strategy NA
Mr. Michael Pitzner Gen. Counsel, Compliance Officer & Sr. VP of Legal NA
Mr. Thomas Schwerzmann VP of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…